# Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

> **NCT07393425** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 50 (estimated)

## Conditions studied

- HER2 + Breast Cancer

## Interventions

- **DRUG:** Trastuzumab Deruxtecan
- **DRUG:** Pertuzumab
- **DRUG:** Taxane Chemotherapy
- **DRUG:** Trastuzumab (or biosimilar)
- **DRUG:** Pyrotinib 320mg

## Key facts

- **NCT ID:** NCT07393425
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-09-30
- **Final completion:** 2032-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07393425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07393425, "Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07393425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*